Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed ... a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

They work by multiple mechanisms but most relevant to PD-1 inhibitors which work by keeping ... estimates of potential markets for drugs under development, clinical trials, actions by the FDA ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

Company advances MICVO into monotherapy and combination clinical trials with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab), targeting recurrent and metastatic head and neck squamous cell ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking ... a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models ...